Viome, GSK to develop cancer, autoimmune disease therapies

By The Science Advisory Board staff writers

October 20, 2021 -- Viome Life Sciences has expanded its partnership with GlaxoSmithKline (GSK) to develop potential therapies for cancer and autoimmune diseases.

Through the collaboration, Viome and GSK will examine the connection between the gut microbiome and the onset of specific chronic disorders. The companies will explore therapies using targets based on Viome's discovery platform, which analyzes host and microbial interaction at the onset and progression of diseases.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.